Eli Lilly's Mounjaro met goal of cardiovascular benefit in head-to-head trial with Trulicity

Clinical Trial Results & Drug Performance - Eli Lilly's diabetes drug, Mjaro, met the goal of a phase three trial by cutting the risk of heart disease in people with type 2 diabetes [1] - The trial showed Mjaro delivered an 8% lower rate of cardiovascular events than Trulicity and a 16% reduction in death from any cause [2] - Data strengthens the case for insurers, particularly in other parts of the world where the drug is launching [3] - One doctor worries the results aren't good enough to convince insurers in the US and might limit coverage of Mjaro since it wasn't significantly better than Trulicity [4] - Analysts were looking for a greater than 10% reduction in cardiovascular events [5] Market & Investor Reaction - The stock experienced a decline of approximately 4% [4] - There was disappointment as the drug didn't show it was significantly better than Trulicity [5][6] Emerging Trends - Plastic surgeons' business is booming due to "Ozempic face" (loose skin from weight loss) [7]